Drug Trial Radar · NCT05164341
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Dec 17, 2021
Primary completion
Jul 14, 2026
Study completion Oct 6, 2026
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Conditions
- Partial Lipodystrophy
Interventions
metreleptinDrug
Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to month 6 in HbA1c in subjects with partial lipodystrophy (PL)Time frame: 6 months
- Percent change from Baseline to month 6 in fasting TGs in subjects with partial lipodystrophy (PL)Time frame: 6 months
Locations
31 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
UC Davis
Sacramento, California
Flourish Boca Raton
Boca Raton, Florida
Emory University
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
University of Missouri
Columbia, Missouri
Amryt Research Site, Endocrinology Research Associates Inc
Columbus, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
UZ Leuven
Leuven, Belgium
Universitário Walter Cantídio
Fortaleza, Brazil
Insight Centro de Pesquisas
Porto Alegre, Brazil
Hospital das Clinicas FMRP-USP
Ribeirão Preto, Brazil
Instituto Estadual de Diabetes e Endocrinologia (IEDE-RJ)
Rio de Janeiro, Brazil
Nova Scotia Health
Halifax, Nova Scotia, Canada
Care Access Clinic
Sydney, Nova Scotia, Canada
Hamilton General Hospital- McMaster University
Hamilton, Ontario, Canada
London Health Science Centre
London, Ontario, Canada
Ecogene-21
Chicoutimi, Quebec, Canada
Faculty of Medicine, Universite Laval
Québec, Quebec, Canada
Universidad Catolica
Santiago, Chile
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
Leids Universitair Medisch Centrum
Leiden, Netherlands
Radboud University Medical Centre Interne Geneeskund
Nijmegen, Netherlands
Uniwersyteckie Centrum Kliniczne
Katowice, Poland
SPZOZ Szpital Uniwersytecki w Krakowie
Krakow, Poland
University Clinical Hospital of Santiago de Compostela/Hospital Universitario
Santiago de Compostela, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.